We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

76 hedge funds and large institutions have $286M invested in Avadel Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 23

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

13% less funds holding

Funds holding: 87 → 76 (-11)

21% less capital invested

Capital invested by funds: $360M → $286M (-$74M)

60% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 15

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $86K

Holders
76
Holders Change
-11
Holders Change %
-12.64%
% of All Funds
1.9%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
6
Increased
24
Reduced
23
Closed
15
Calls
–
Puts
$86K
Net Calls
-$86K
Net Calls Change
+$960K

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$3.58M
2
Deutsche Bank
Deutsche Bank
Germany
+$3.31M
3
AC
Armistice Capital
New York
+$2.51M
4
HA
Heartland Advisors
Wisconsin
+$1.23M
5
Morgan Stanley
Morgan Stanley
New York
+$1.2M

Top Sellers

Rank Fund Capital Flow
1
JGC
J. Goldman & Co
New York
-$10.2M
2
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$5.46M
3
PCM
Portolan Capital Management
Massachusetts
-$5.04M
4
IHM
Iguana Healthcare Management
New York
-$4.96M
5
Asset Management One
Asset Management One
Japan
-$2.96M
Name Holding Trade Value Shares
Change 		Change in
Stake
IHM
76
Iguana Healthcare Management
New York
– -$4.96M -400,000 Closed
Asset Management One
77
Asset Management One
Japan
– -$2.96M -245,862 Closed
Millennium Management
78
Millennium Management
New York
– -$2.03M -163,884 Closed
B
79
Bailard
California
– -$1.5M -120,700 Closed
CS
80
Candriam SCA
Luxembourg
– -$1.38M -111,000 Closed
DC
81
Deere & Company
Illinois
– -$544K -43,887 Closed
EVM
82
Eaton Vance Management
Massachusetts
– -$430K -34,700 Closed
Geode Capital Management
83
Geode Capital Management
Massachusetts
– -$275K -22,218 Closed
VKH
84
Virtu KCG Holdings
New York
– -$240K -19,366 Closed
EMG
85
Ellington Management Group
Connecticut
– -$184K -14,800 Closed
BFM
86
Boothbay Fund Management
New York
– -$128K -10,300 Closed
AIM
87
Acrospire Investment Management
Illinois
– -$37K -2,955 Closed
ST
88
Spot Trading
Illinois
– -$36K -2,900 Closed
WC
89
Whitnell & Co
Illinois
– -$6K -500 Closed
Manulife (Manufacturers Life Insurance)
90
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– +$198 +18 New
1 2 3
4

AVDL Hedge Fund Activity: Q4 2016 in Review

76 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q4 2016, worth a combined $286M — down 21% from $360M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of AVDL and 6 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 24 added.

The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $3.58M. The largest seller was J. Goldman & Co, exiting entirely with an estimated $10.2M sold.

  • 76 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q4 2016, down from 87 in Q3 2016.
  • Funds reported $286M of Avadel Pharmaceuticals stock for Q4 2016, down 21% quarter-over-quarter.
  • 6 funds opened new Avadel Pharmaceuticals positions in Q4 2016 and 15 closed out, a net change of -9 holders.
  • The largest Avadel Pharmaceuticals buyer in Q4 2016 was Stonepine Capital Management, an estimated $3.58M added.
  • The largest Avadel Pharmaceuticals seller in Q4 2016 was J. Goldman & Co, an estimated $10.2M sold.

Based on aggregated 13F filings for Q4 2016.